System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof E. Ferrari is an expert in Cardiology at Hôpital Pasteur (France). As of October 2026, ScienceLeadR ranks E. Ferrari in the top 1% of experts worldwide for Embolism and Thrombosis and Myocardial Ischemia. E. Ferrari has authored 665 publications, the most recent in 2026, and is an investigator in 50 clinical trials, 7 of them ongoing. SLR score: 2,277 (community average: 125). How the SLR is computed.

LeadR Profile

Prof E. Ferrari Hôpital Pasteur France
2 277 ScienceLeadR Reputation 2277

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Hematology - Public Health - Biostatistics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Hôpital Pasteur

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 665

Citations

Citations: 41 467 1st author: 125 Last author: 163 Unique author: 14

Main journals

Presse Med 40
N Engl J Med 22
Arch Mal Coeur Vaiss 21
Eur Heart J 17
Archives of Cardiovascular Diseases Supplements 16

Best Journals

N Engl J Med 22
Lancet 5
Circulation 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PMID 42669300 — myocardial infarction, heart failure, heart, therapeutics		Lancet Top journal20262
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
PMID 42666092 — cholesterol, ldl, myocardial infarction, percutaneous coronary intervention, cholesterol, odds ratio, therapeutics		JAMA Top journal20262
Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction: A Post Hoc Analysis of the MINT Randomized Clinical Trial.
PMID 42507445 — hemoglobins, myocardial infarction, anemia, heart failure, probability, heart, clinical medicine		JAMA Netw Open20260
Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.
PMID 42373176 — diabetes mellitus, cholesterol, ldl, lipoproteins, cholesterol, therapeutics, lipoproteins, ldl		BMJ Open20260
Heart Rate and Cardiovascular Outcomes in Post-Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial.
PMID 42267437 — mortality, stroke, myocardial infarction, heart rate, heart, reperfusion, therapeutics, blood circulation		Circulation Top journal20260

Clinical Studies 50

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 30
N/A 11
Phase 4 7
Phase 1/Phase 2 1
Phase 2 1

By status:

Completed 35
Recruiting 7
Terminated 4
Unknown 2
Active not recruiting 1
Withdrawn 1

By type:

Interventional 41
Observational 9

By Monocentric/Multicentric:

monocentric 16
multicentric2to4 1
multicentric5to9 3
multicentricup10 30

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Rituximab in patients with ST elevation myocardial infarction A phase 2 placebo controlled randomized clinical trial
2022-501893-21-00 — myocardial infarction, st elevation myocardial infarction, rituximab		Phase 2Recruiting2022
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00 — hypertension, safety, healthy volunteers, pulmonary arterial hypertension, therapeutics, pharmacokinetics		Phase 1/Phase 2Recruiting2025
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and or Chronic Kidney Disease (ATTAIN Outcomes)
2025-523123-22-00 — kidney diseases, incidence, cardiovascular diseases, kidney, atherosclerosis		Phase 3Recruiting2026
EASi PROTKT A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes high blood pressure and cardiovascular disease
2025-521188-11-00 — diabetes mellitus, hypertension, safety, blood, cardiovascular diseases, blood pressure, diabetes mellitus, type 2		Phase 3Recruiting2025
OCEAN(a) CCTA Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Coronary Computed Tomography Angiography trial
2025-521117-88-00 — safety, tomography, lipoproteins, cardiovascular diseases, multiple chronic conditions, angiography, arteries, lipoprotein(a), computed tomography angiography		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS